In this episode, Jack and Jen welcome special guest Nico Renner, Patient Partnership Lead at Roche, to discuss the transformative impact of social media on patient engagement. Together they explore how pharmaceutical companies can embrace this shift to enhance patient interaction and outcomes.
Podcast Tags: healthcare, life sciences, patient engagement, patient centricity, patient outcomes, social media, metrics, innovation
Disclaimer: Nico is sharing his own opinions, which might not necessarily reflect Roche’s perspective
Check out Nico’s profile LinkedIn profile here: https://www.linkedin.com/in/nicorenner/
Source Links:
Panel – Jack Young, Nico Renner and Jen Burke
Research & Production – Jack Young, Nico Renner and Jen Burke
Recording & Editing –Rachel Skonecki
For additional discussion, please contact us at TrendingHealth.com or share a voicemail at
1-888-VYNAMIC.
Vynamic, an Inizio Advisory company, is a leading management consulting partner to global health organizations across Life Sciences, Health Services, and Health Technology. Founded and headquartered in Philadelphia, Vynamic has offices in Boston, Durham NC, New York, and London. Our purpose is simple: We believe there is a better way. We are passionate about shaping the future of health, and for more than 20 years we’ve helped clients transform by connecting strategy to action.
Through a structured, yet flexible delivery model, our accomplished leaders work as an extension of client teams, enabling growth, performance, and culture. Vynamic has been recognized by organizations like Great Place to Work and Business Culture Awards for being leaders and innovators in consulting, company culture, and health. Visit Vynamic.com to discover how we can help transform your
organization or your career.
In today’s fast-paced environment of product launch, planning and preparation aren’t just important—they are...
Listen nowIn this Trending Health Series, Vynamic Product Launch leaders will share their experience partnering with teams across...
Listen nowLayoffs at U.S. health agencies, IRA, and budget cuts disrupt pharma—learn how life sciences can adapt and stay resilient.
Read more